参考文献
关键文献
Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.全文 摘要
Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.全文 摘要
World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Sep 2022 [internet publication].全文
Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.全文 摘要
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].全文
Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. 摘要
World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication].全文
Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. 摘要
National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Mycobacterium tuberculosis infection and disease. Feb 2022 [internet publication].全文
American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005 Nov 1;172(9):1169-227.全文 摘要
参考文献
1. World Health Organization. Health topics: tuberculosis [internet publication].全文
2. World Health Organization. Global tuberculosis report 2022. Oct 2022 [internet publication].全文
3. Dye C. Global epidemiology of tuberculosis. Lancet. 2006 Mar 18;367(9514):938-40. 摘要
4. GBD 2019 Tuberculosis Collaborators. Global, regional, and national sex differences in the global burden of tuberculosis by HIV status, 1990-2019: results from the Global Burden of Disease Study 2019. Lancet Infect Dis. 2022 Feb;22(2):222-41.全文 摘要
5. Centers for Disease Control and Prevention. Latent TB infection in the United States – published estimates. Jan 2022 [internet publication].全文
6. Centers for Disease Control and Prevention. Reported tuberculosis in the United States, 2021. Nov 2022 [internet publication].全文
7. Schildknecht KR, Pratt RH, Feng PI, et al. Tuberculosis - United States, 2022. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):297-303.全文 摘要
8. Lienhardt C. From exposure to disease: the role of environmental factors in susceptibility to an development of tuberculosis. Epidemiol Rev. 2001 Jul;23(2):288-301. 摘要
9. Nahid P, Dorman SE, Alipanah N, et al. Official American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America clinical practice guidelines: treatment of drug-susceptible tuberculosis. Clin Infect Dis. 2016 Oct 1;63(7):e147-95.全文 摘要
10. Lin HH, Ezzati M, Murray M. Tobacco smoke, indoor air pollution and tuberculosis: a systematic review and meta-analysis. PLoS Med. 2007 Jan;4(1):e20.全文 摘要
11. Marks SM, Taylor Z, Qualls NL, et al. Outcomes of contact investigations of infectious tuberculosis patients. Am J Respir Crit Care Med. 2000 Dec;162(6):2033-8.全文 摘要
12. Lewinsohn DM, Leonard MK, LoBue PA, et al. Official American Thoracic Society/Infectious Diseases Society of America/Centers for Disease Control and Prevention clinical practice guidelines: diagnosis of tuberculosis in adults and children. Clin Infect Dis. 2017 Jan 15;64(2):e1-33.全文 摘要
13. Zuber PL, McKenna MT, Binkin NJ, et al. Long-term risk of tuberculosis among foreign-born persons in the United States. JAMA. 1997 Jul 23-30;278(4):304-7. 摘要
14. Markowitz N, Hansen NI, Hopewell PC, et al. Incidence of tuberculosis in the United States among HIV-infected persons. Ann Intern Med. 1997 Jan 15;126(2):123-32. 摘要
15. Toossi Z, Mayanja-Kizza H, Hirsch CS, et al. Impact of tuberculosis on HIV-1 activity in dually infected patients. Clin Exp Immunol. 2001 Feb;123(2):233-8.全文 摘要
16. Daley CL, Small PM, Schechter GF, et al. An outbreak of tuberculosis with accelerated progression among persons infected with human immunodeficiency syndrome. N Engl J Med. 1992 Jan 23;326(4):231-5. 摘要
17. Selwyn PA, Hartel D, Lewis VA, et al. A prospective study of the risk of tuberculosis among intravenous drug users with human immunodeficiency virus infection. N Engl J Med. 1989 Mar 2;320(9):545-50. 摘要
18. Jick SS, Lieberman ES, Rahman MU, et al. Glucocorticoid use, other associated factors, and the risk of tuberculosis. Arthritis Rheum. 2006 Feb 15;55(1):19-26. 摘要
19. Wallis RS, Broder MS, Wong JY, et al. Granulomatous infections due to tumor necrosis factor blockade: correction. Clin Infect Dis. 2004 Oct 15;39(8):1254-5. 摘要
20. Kamboj M, Sepkowitz KA. The risk of tuberculosis in patients with cancer. Clin Infect Dis. 2006 Jun 1;42(11):1592-5. 摘要
21. American Thoracic Society. Targeted tuberculin testing and treatment of latent tuberculosis infection. Am J Respir Crit Care Med. 2000 Apr;161(4 Pt 2):S221-47.全文 摘要
22. International Union Against Tuberculosis Committee on Prophylaxis. Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. Bull World Health Organ. 1982;60(4):555-64. 摘要
23. Li M, Chen T, Hua Z, et al. Global, regional, and national prevalence of diabetes mellitus in patients with pulmonary tuberculosis: a systematic review and meta-analysis. Diabetol Metab Syndr. 2021 Oct 30;13(1):127.全文 摘要
24. Cantwell MF, McKenna MT, McCray E, et al. Tuberculosis and race/ethnicity in the United States, impact of socioeconomic status. Am J Respir Crit Care Med. 1998 Apr;157(4 Pt 1):1016-20.全文 摘要
25. Wang EY, Arrazola RA, Mathema B, et al. The impact of smoking on tuberculosis treatment outcomes: a meta-analysis. Int J Tuberc Lung Dis. 2020 Feb 1;24(2):170-5. 摘要
26. Colditz GA, Berkey CS, Mosteller F, et al. The efficacy of bacillus Calmette-Guérin vaccination of newborns and infants in the prevention of tuberculosis: meta-analyses of the published literature. Pediatrics. 1995 Jul;96(1 Pt 1):29-35. 摘要
27. Mangtani P, Abubakar I, Ariti C, et al. Protection by BCG vaccine against tuberculosis: a systematic review of randomized controlled trials. Clin Infect Dis. 2014 Feb;58(4):470-80.全文 摘要
28. Katelaris AL, Jackson C, Southern J, et al. Effectiveness of BCG vaccination against Mycobacterium tuberculosis infection in adults: a cross-sectional analysis of a UK-based cohort. J Infect Dis. 2020 Jan 1;221(1):146-55.全文 摘要
29. UK Health Security Agency. BCG vaccination programme. Documents relating to the Bacillus Calmette–Guérin (BCG) vaccination programme. Oct 2021 [internet publication].全文
30. World Health Organization. WHO consolidated guidelines on tuberculosis: module 5: management of tuberculosis in children and adolescents. Sep 2022 [internet publication].全文
31. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - tuberculosis. May 2023 [internet publication].全文
32. Centers for Disease Control and Prevention. CDC Yellow Book 2024: health information for international travel. Section 5: travel-associated infections & diseases - perspectives: testing travelers for mycobacterium tuberculosis infection. May 2023 [internet publication].全文
33. Centers for Disease Control and Prevention (CDC). Updated guidelines for the use of nucleic acid amplification tests in the diagnosis of tuberculosis. MMWR Morb Mortal Wkly Rep. 2009 Jan 16;58(1):7-10.全文 摘要
34. World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: rapid diagnostics for tuberculosis detection. Jul 2021 [internet publication].全文
35. Zifodya JS, Kreniske JS, Schiller I, et al. Xpert Ultra versus Xpert MTB/RIF for pulmonary tuberculosis and rifampicin resistance in adults with presumptive pulmonary tuberculosis. Cochrane Database Syst Rev. 2021 Feb 22;(2):CD009593.全文 摘要
36. Shapiro AE, Ross JM, Yao M, et al. Xpert MTB/RIF and Xpert Ultra assays for screening for pulmonary tuberculosis and rifampicin resistance in adults, irrespective of signs or symptoms. Cochrane Database Syst Rev. 2021 Mar 23;(3):CD013694.全文 摘要
37. Pillay S, Steingart KR, Davies GR, et al. Xpert MTB/XDR for detection of pulmonary tuberculosis and resistance to isoniazid, fluoroquinolones, ethionamide, and amikacin. Cochrane Database Syst Rev. 2022 May 18;(5):CD014841.全文 摘要
38. Haraka F, Kakolwa M, Schumacher SG, et al. Impact of the diagnostic test Xpert MTB/RIF on patient outcomes for tuberculosis. Cochrane Database Syst Rev. 2021 May 6;(5):CD012972.全文 摘要
39. Kay AW, Ness T, Verkuijl SE, et al. Xpert MTB/RIF Ultra assay for tuberculosis disease and rifampicin resistance in children. Cochrane Database Syst Rev. 2022 Sep 6;(9):CD013359.全文 摘要
40. Laursen LL, Dahl VN, Wejse C. Stool testing for pulmonary TB diagnosis in adults. Int J Tuberc Lung Dis. 2022 Jun 1;26(6):516-23. 摘要
41. Bjerrum S, Schiller I, Dendukuri N, et al. Lateral flow urine lipoarabinomannan assay for detecting active tuberculosis in people living with HIV. Cochrane Database Syst Rev. 2019 Oct 21;(10):CD011420.全文 摘要
42. Nathavitharana RR, Lederer P, Chaplin M, et al. Impact of diagnostic strategies for tuberculosis using lateral flow urine lipoarabinomannan assay in people living with HIV. Cochrane Database Syst Rev. 2021 Aug 20;(8):CD014641.全文 摘要
43. Behr MA, Warren SA, Salamon H, et al. Transmission of Mycobacterium tuberculosis from patients smear-negative for acid-fast bacilli. Lancet. 1999 Feb 6;353(9151):444-9. 摘要
44. Metcalfe JZ, Everett CK, Steingart KR, et al. Interferon-γ release assays for active pulmonary tuberculosis diagnosis in adults in low- and middle-income countries: systematic review and meta-analysis. J Infect Dis. 2011 Nov 15;204 (suppl 4):S1120-9.全文 摘要
45. Nolt D, Starke JR. Tuberculosis infection in children and adolescents: testing and treatment. Pediatrics. 2021 Dec 1;148(6):e2021054663.全文 摘要
46. Pai M, Zwerling A, Menzies D. Systematic review: T-cell-based assays for the diagnosis of latent tuberculosis infection: an update. Ann Intern Med. 2008 Aug 5;149(3):177-84. 摘要
47. Mazurek GH, Jereb J, Vernon A, et al; IGRA Expert Committee; Centers for Disease Control and Prevention (CDC). Updated guidelines for using Interferon Gamma Release Assays to detect Mycobacterium tuberculosis infection - United States, 2010. MMWR Recomm Rep. 2010 Jun 25;59(RR-5):1-25.全文 摘要
48. Doherty SD, Van Voorhees A, Lebwohl MG, et al. National Psoriasis Foundation consensus statement on screening for latent tuberculosis infection in patients with psoriasis treated with systemic and biologic agents. J Am Acad Dermatol. 2008 Aug;59(2):209-17. 摘要
49. World Health Organization. WHO consolidated guidelines on tuberculosis: module 3: diagnosis: tests for TB infection. Sep 2022 [internet publication].全文
50. Miller LG, Asch SM, Yu EI, et al. A population-based survey of tuberculosis symptoms: how atypical are atypical presentations. Clin Infect Dis. 2000 Feb;30(2):293-9. 摘要
51. Geng E, Kreiswirth B, Burzynski J, et al. Clinical and radiographic correlates of primary and reactivation tuberculosis, a molecular epidemiology study. JAMA. 2005 Jun 8;293(22):2740-5. 摘要
52. Jones BE, Ryu R, Yang Z, et al. Chest radiographic findings in patients with tuberculosis with recent or remote infection. Am J Respir Crit Care Med. 1997 Oct;156(4 Pt 1):1270-3.全文 摘要
53. Global Laboratory Initiative. Mycobacteriology laboratory manual. Apr 2014 [internet publication].全文
54. Garay SM. Pulmonary tuberculosis. In: Rom WM, Garay SM, eds. Tuberculosis. 2nd ed. New York: Lippincott, Williams & Wilkins; 2003:345-94.
55. Pai M, Menzies D. Interferon-release assays: what is their role in the diagnosis of active tuberculosis. Clin Infect Dis. 2007 Jan 1;44(1):74-7. 摘要
56. Dewan PK, Grinsdale J, Kawamura LM. Low sensitivity of a whole-blood interferon-gamma release assay for detection of active tuberculosis. Clin Infect Dis. 2007 Jan 1;44(1):69-73. 摘要
57. Biscione F, Cecchini D, Ambrosioni J, et al. Nocardiosis in patients with human immunodeficiency virus infection [in Spanish]. Enferm Infecc Microbiol Clin. 2005 Aug-Sep;23(7):419-23. 摘要
58. Yildiz O, Doganay M. Actinomycoses and Nocardia pulmonary infections. Curr Opin Pulm Med. 2006 May;12(3):228-34. 摘要
59. Centers for Disease Control and Prevention. Tuberculosis (TB) (Mycobacterium tuberculosis) 2009 case definition. 2009 [internet publication].全文
60. World Health Organization. Definitions and reporting framework for tuberculosis - 2013 revision (updated December 2014 and January 2020). Jan 2020 [internet publication].全文
61. U.S. Preventive Services Task Force. Latent tuberculosis infection in adults: screening. May 2023 [internet publication].全文
62. Sosa LE, Njie GJ, Lobato MN, et al. Tuberculosis screening, testing, and treatment of US health care personnel: recommendations from the National Tuberculosis Controllers Association and CDC, 2019. MMWR Morb Mortal Wkly Rep. 2019 May 17;68(19):439-43.全文 摘要
63. Vonasek B, Ness T, Takwoingi Y, et al. Screening tests for active pulmonary tuberculosis in children. Cochrane Database Syst Rev. 2021 Jun 28;(6):CD013693.全文 摘要
64. Van't Hoog A, Viney K, Biermann O, et al. Symptom- and chest-radiography screening for active pulmonary tuberculosis in HIV-negative adults and adults with unknown HIV status. Cochrane Database Syst Rev. 2022 Mar 23;(3):CD010890.全文 摘要
65. World Health Organization. WHO consolidated guidelines on tuberculosis: module 2: screening: systematic screening for tuberculosis disease. Mar 2021[internet publication].全文
66. World Health Organization. WHO consolidated guidelines on tuberculosis: module 1: prevention: tuberculosis preventive treatment. Mar 2021 [internet publication].全文
67. Nahid P, Mase SR, Migliori GB, et al. Treatment of drug-resistant tuberculosis. An official ATS/CDC/ERS/IDSA clinical practice guideline. Am J Respir Crit Care Med. 2019 Nov 15;200(10):e93-142.全文 摘要
68. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-susceptible tuberculosis treatment. May 2022 [internet publication].全文
69. Karumbi J, Garner P. Directly observed therapy for treating tuberculosis. Cochrane Database Syst Rev. 2015 May 29;2015(5):CD003343.全文 摘要
70. Jasmer RM, Seaman CB, Gonzalez L, et al. Tuberculosis treatment outcomes: directly observed therapy compared with self administered therapy. Am J Respir Crit Care Med. 2004 Sep 1;170(5):561-6.全文 摘要
71. Mangan JM, Woodruff RS, Winston CA, et al. Recommendations for Use of Video Directly Observed Therapy During Tuberculosis Treatment - United States, 2023. MMWR Morb Mortal Wkly Rep. 2023 Mar 24;72(12):313-316.全文 摘要
72. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: tuberculosis care and support. Jul 2022 [internet publication].全文
73. Dorman SE, Nahid P, Kurbatova EV, et al. Four-month rifapentine regimens with or without moxifloxacin for tuberculosis. N Engl J Med. 2021 May 6;384(18):1705-18.全文 摘要
74. Critchley JA, Orton LC, Pearson F. Adjunctive steroid therapy for managing pulmonary tuberculosis. Cochrane Database Syst Rev. 2014 Nov 12;2014(11):CD011370.全文 摘要
75. Abdool Karim SS, Naidoo K, Grobler A, et al. Integration of antiretroviral therapy with tuberculosis treatment. N Engl J Med. 2011 Oct 20;365(16):1492-501.全文 摘要
76. Havlir DV, Kendall MA, Ive P, et al; AIDS Clinical Trials Group Study A5221. Timing of antiretroviral therapy for HIV-1 infection and tuberculosis. N Engl J Med. 2011 Oct 20;365(16):1482-91.全文 摘要
77. Uthman OA, Okwundu C, Gbenga K, et al. Optimal timing of antiretroviral therapy initiation for HIV-infected adults with newly diagnosed pulmonary tuberculosis: a systematic review and meta-analysis. Ann Intern Med. 2015 Jul 7;163(1):32-9. 摘要
78. Manosuthi W, Kiertiburanakul S, Phoorisri T, et al. Immune reconstitution inflammatory syndrome of tuberculosis among HIV-infected patients receiving antituberculous and antiretroviral therapy. J Infect. 2006 Dec;53(6):357-63. 摘要
79. US Food and Drug Administration. FDA Drug Safety Communication: FDA updates warnings for oral and injectable fluoroquinolone antibiotics due to disabling side effects. Dec 2018 [internet publication].全文
80. US Food & Drug Administraton. FDA reinforces safety information about serious low blood sugar levels and mental health side effects with fluoroquinolone antibiotics; requires label changes. Jul 2018 [internet publication].全文
81. World Health Organization. WHO consolidated guidelines on tuberculosis: module 4: treatment: drug-resistant tuberculosis treatment, 2022 update. Dec 2022 [internet publication].全文
82. World Health Organization. WHO announces updated definitions of extensively drug-resistant tuberculosis. Jan 2021 [internet publication].全文
83. Conradie F, Diacon AH, Ngubane N, et al. Treatment of highly drug-resistant pulmonary tuberculosis. N Engl J Med. 2020 Mar 5;382(10):893-902.全文 摘要
84. Nyang'wa BT, Berry C, Kazounis E, et al. A 24-week, all-oral regimen for rifampin-resistant tuberculosis. N Engl J Med. 2022 Dec 22;387(25):2331-43.全文 摘要
85. Tuberculosis Trials Consortium. Rifapentine and isoniazid once a week versus rifampicin and isoniazid twice a week for treatment of drug-susceptible pulmonary tuberculosis in HIV-negative patients: a randomised clinical trial. Lancet. 2002 Aug 17;360(9332):528-34. 摘要
86. National Institutes of Health, Centers for Disease Control and Prevention, HIV Medicine Association, and Infectious Diseases Society of America. Guidelines for the prevention and treatment of opportunistic infections in adults and adolescents with HIV. Mycobacterium tuberculosis infection and disease. Feb 2022 [internet publication].全文
87. Esmail A, Oelofse S, Lombard C, et al. An all-oral 6-month regimen for multidrug-resistant tuberculosis: a multicenter, randomized controlled clinical trial (the NExT study). Am J Respir Crit Care Med. 2022 May 15;205(10):1214-27. 摘要
88. Paton NI, Cousins C, Suresh C, et al. Treatment strategy for rifampin-susceptible tuberculosis. N Engl J Med. 2023 Mar 9;388(10):873-87.全文 摘要
89. Tait DR, Hatherill M, Van Der Meeren O, et al. Final analysis of a trial of M72/AS01E vaccine to prevent tuberculosis. N Engl J Med. 2019 Dec 19;381(25):2429-39.全文 摘要
90. World Health Organization. Vaccines and immunization: investigational vaccine candidate M72/AS01E. Jun 2020 [internet publication].全文
91. Anyama N, Bracebridge S, Black C, et al. What happens to people diagnosed with tuberculosis? A population-based cohort. Epidemiol Infect. 2007 Oct;135(7):1069-76. 摘要
92. Fielder JF, Chaulk CP, Dalvi M, et al. A high tuberculosis case-fatality rate in a setting of effective tuberculosis control: implications for acceptable treatment success rates. Int J Tuberc Lung Dis. 2002 Dec;6(12):1114-7. 摘要
93. Penner C, Roberts D, Kunimoto D, et al. Tuberculosis as a primary cause of respiratory failure requiring mechanical ventilation. Am J Respir Crit Care Med. 1995 Mar;151(3 Pt 1):867-72. 摘要
94. American Thoracic Society/Centers for Disease Control and Prevention/Infectious Diseases Society of America. Controlling tuberculosis in the United States. Am J Respir Crit Care Med. 2005 Nov 1;172(9):1169-227.全文 摘要
95. Narita M, Ashkin D, Hollender ES, et al. Paradoxical worsening of tuberculosis following antiretroviral therapy in patients with AIDS. Am J Respir Crit Care Med. 1998 Jul;158(1):157-61.全文 摘要
96. Cheng V, Ho P, Lee R, et al. Clinical spectrum of paradoxical deterioration during antituberculosis therapy in non-HIV-infected patients. Eur J Clin Microbiol Infect Dis. 2002 Nov;21(11):803-9. 摘要
97. Santiago S, Tobias J, Williams AJ. A reappraisal of the causes of hemoptysis. Arch Intern Med. 1991 Dec;151(12):2449-51. 摘要
98. Johnston H, Reisz G. Changing spectrum of hemoptysis. Underlying causes in 148 patients undergoing diagnostic flexible fiberoptic bronchoscopy. Arch Intern Med. 1989 Jul;149(7):1666-8. 摘要
99. World Health Organization. Tuberculosis and air travel: guidelines for prevention and control. 2008 [internet publication].全文
内容使用需遵循免责声明